Bicycle Therapeutics PLC Sponsored ADR

BCYC

Healthcare Biotechnology

Bicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024.

Revenue
+190.2%
EPS
+82.4%
Free cash flow
+43.5%

Quarter to September 2026, against a year earlier

3.61 0.13 +3.74%
Market cap
$182.5M
P/E
n/m
Fwd P/E
n/m
Dividend yield
—
F-score
2/9
ROIC
−279.8%
Net debt / EBITDA
2.6×
Dividend safety
n/a

Bicycle Therapeutics PLC Sponsored ADR (BCYC) P/E ratio

Alert me on P/E ratio

Bicycle Therapeutics PLC Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
31 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

Company P/E ratio
TRDA Entrada Therapeutics, Inc. compare n/m
BCYC Bicycle Therapeutics PLC Sponsored ADR n/m
WHWK Whitehawk Therapeutics, Inc. compare n/m
MDWD MediWound Ltd. compare n/m
BBOT BridgeBio Oncology Therapeutics, Inc compare n/m
UPB Upstream Bio, Inc. compare n/m
IVVD Invivyd, Inc. compare n/m
ACOG Alpha Cognition Inc. compare n/m
CGEN Compugen Ltd. compare 5.2×
Biotechnology industry median 10.6×
Healthcare sector median 24.5×
Market median 17.8×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on BCYC